SLC5A2 and diabetic kidney disease: We specifically aimed at assessing the interference of SGLT2 inhibition with tubular inflammatory response mechanisms that are essential for the initial pathogenesis of both diabetic and non-diabetic nephropathies, by utilizing IL-1β as a pro-inflammatory ligand and Empa.